Pablo Mando

Clinical Oncologist, Breast and Gyn Unit, CEMIC, Buenos Aires, Argentina. YOC member @myESMO @SUMAargentina Board member

[Pablo Mando @PabloMando]

@PTarantinoMD Hate it 😡

[Pablo Mando @PabloMando]

@PTarantinoMD @LACOG_group @GustavoWerutsky Amazing lecture. Enjoyed it a lot 👏👏👏

[Pablo Mando @PabloMando]

@renata_bonadio @OncoAlert @PTarantinoMD @JavierCortesMD @RebeccaDSing @hmcarthur @ASCO Nada, Nothing, Niente, Nichts, Rien

[Pablo Mando @PabloMando]

@barrosonco Esta actualizadisima la mia @barrosonco

[ESMO - Eur. Oncology @myESMO]

#ESMOMembers 📢 Voting for the ESMO President 2029-2030 is open. #ESMOElections
An invitation from @FAndreMD to learn more about the candidates and their vision for the Society.
Cast your vote 🔗https://t.co/igOnURJZpJ

[Pablo Mando @PabloMando]

Back in Berlin this year! Growing year after year. Led by amazing @stolaney1 @myESMO #ESMOBreast26

[Benjamin Walbaum, MD @benjiwal]

Weekly #BreastCancer Newsletter- My take of last week’s publications from select high-impact journals (April 13 - April 19, 2026).
@OncoDailyBreast
@oncodaily
#BCSM #BreastCancerResearch #BreastCancer

[Pablo Mando @PabloMando]

@myESMO Preceptorship on Breast Cancer starting in Bogota! A must in LATAM every year. People from 🇨🇴🇧🇷🇲🇽🇦🇷🇵🇪🇨🇱🇧🇴🇻🇪

[Aumilto Silva, MD. @aumilto]

A recent multicentre study in Lancet Oncology demonstrates that a multimodal deep learning model can predict Oncotype DX recurrence scores directly from H&E histopathology with high accuracy (AUC ~0.90) and consistent external validation across diverse cohorts.

• AUC 0.898 for RS ≥26
• r=0.73 vs genomic score
• External AUC 0.86–0.90
• HR 2.6–2.9 for recurrence endpoints

Overall, this work represents a significant step toward integrating digital pathology and AI into therapeutic decision-making in breast cancer. Prospective trials are required before clinical implementation.
@dviramar2 @TheLancetOncol @OncoAlert

👉 https://t.co/OpkYJPIMtG

[Paolo Tarantino @PTarantinoMD]

40 years ago, a young physician submitted a paper reporting on the alteration of a gene called HER2/neu to Science. He didn’t know that it was the beginning of one of the most remarkable scientific stories of the human kind, which would eventually impact the lives of COUNTLESS patients with cancer — first via mABs, then through ADCs, bsAbs and beyond.

Unforgettable Keynote presentation by Dennis Slamon at #MBCC26.

[ESMO - Eur. Oncology @myESMO]

Do you have an impactful research idea?

One that could improve patient care or advance scientific excellence?

Apply for the ESMO Leadership & Career Development Award, offering protected research time, leadership & communication training by 3 May 26

🔗https://t.co/D9zzaCsxzy

#Oncology #ESMOYOC

@TeresaSAmaral 
@E_de_Azambuja 
@DrAngelaLamarca
@Rodrosb

[OncoDaily @oncodaily]

New Real-Life Evidence on Adjuvant CDK4/6 Inhibitors in Colombia - Alfredo Sebastián Golemba

@PabloMando

https://t.co/jxD7lXS4ky

#OncoDaily #Oncology #Cancer #Health #Medicine #MedX

[ESMO - Eur. Oncology @myESMO]

📣 #ESMOBreast26: One week left to share your studies! The field of breast cancer research is advancing rapidly — and your work can help shape the next breakthroughs.
⏰ Deadline: 27 January 2026

🔗 https://t.co/8B3DWJP9u3

#esmomeetings

[Pablo Mando @PabloMando]

The main reason for being there was to give a voice to young oncologists in Latin America. An excellent spokesperson remains to represent us and make our needs visible @GuiNaderMarta We'll stay in touch!!!

[Pablo Mando @PabloMando]

With nostalgia, I must say that my time at @myESMO YOC ends. 3 spectacular years of growth shared with wonderful friends. I want to thank everyone who supported and motivated me, especially @AndresC27622123 @E_de_Azambuja @matteolambe @Rodrosb ⬇️

[Pablo Mando @PabloMando]

📣Nueva edicion del @myESMO Virtual Mentorship Programme. Actividad recomendada para jovenes oncologos de latinoamerica! Programa de 12 meses que ofrece la oportunidad de ser emparejados con mentor de ESMO, quien brindará una mentoría 1:1. 📆 deadline 15/2
https://t.co/H9YufWakWQ

[Rodrigo Sánchez-Bayona @Rodrosb]

💭Can you imagine that you had a tool that could predict the risk of developing brain mets in pts with HER2+ MBC?

😮Stop dreaming, this is real
🎯New generation biomarkers
🌍 International colab, 215 pts
Come by and discuss our poster at #SABCS25 on Dec 12th
@OncoAlert

[Pablo Mando @PabloMando]

@Muller_Lab @myESMO @matteolambe @PTarantinoMD @E_de_Azambuja @stolaney1 @Rodrosb @ElisaAgostinett @ErikaHamilton9 @hoperugo @DrRBarroso @MVidalMD @benjiwal @anelcabrera DESTINY-Breast 11

[Pablo Mando @PabloMando]

HER eBC management is improving survival but more complex. Here is a proposed algorithm with new advances post @myESMO #ESMO25 What do you think? What would you change? @matteolambe @PTarantinoMD @E_de_Azambuja @stolaney1 @Rodrosb @ElisaAgostinett @ErikaHamilton9 @hoperugo

[Antonio Giordano, MD PhD @antgiorda]

Joined @DrHBurstein contest during #ESMO25 @myESMO review: proposed algorithm for first- and second-line #EndocrineTherapy in ER-positive/HER2-negative metastatic #BreastCancer @OncoAlert

[Asociación Argentina de Oncología Clínica (AAOC) @aaoncoclinica]

Link de inscripción al Ciclo 2025:
https://t.co/N6I4Ud1OH2